Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A yellow fever virus NS4B inhibitor not only suppresses viral replication, but also enhances the virus activation of RIG-I-like receptor-mediated innate immune response

PLoS Pathogens(2022)10.1371/journal.ppat.1010271Source: DataRank Database

A yellow fever virus NS4B inhibitor not only suppresses viral replication, but also enhances the virus activation of RIG-I-like receptor-mediated innate immune response is a research paper published in PLoS Pathogens (2022). On theSindex it has a DataRank of 0. It has been cited 23 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access23 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 3.87)OA: goldTopics (47)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Xuexiang Zhang ORCID,Lin Zhang ORCID,Shuo Wu ORCID,Julia Ma ORCID,Fuxuan Wang ORCID

Live enrichment

PubMed:35061864 PMC:PMC8809586 OpenAlex:https://openalex.org/W4206918183

National Institutes of Health

Grant: AI134732

NIAID NIH HHS

Grant: R01 AI134732

National Institutes of Health

Grant: 1R01AI134732-01A1

Development of Benzodiazepine YFV NS4B inhibitors as therapeutic agents for Yellow Fever

Hepatitis B Foundation and appropriation from the Commonwealth of Pennsylvania

FWCI

3.87

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1010271&type=printable

publisherhttps://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1010271&type=printable

publisherhttps://dx.plos.org/10.1371/journal.ppat.1010271

journalhttps://doi.org/10.1371/journal.ppat.1010271

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35061864

Fields of Study

Mosquito-borne diseases and controlinterferon and immune responsesViral Infections and Vectors0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

DEAD Box Protein 58Antiviral AgentsBenzodiazepinesCell LineHumansImmunity, InnateVirus ReplicationYellow FeverYellow fever virusViral Nonstructural Proteins

Keywords

Viral replicationInnate immune systemBiologyVirologyMDA5InterferonVirusCell biologyTLR3FlavivirusImmune systemRNARNA interferenceToll-like receptorImmunologyGeneQH301-705.5RC581-607Viral Nonstructural ProteinsVirus ReplicationAntiviral AgentsImmunity, InnateCell LineBenzodiazepinesYellow FeverDEAD Box Protein 58HumansImmunologic diseases. AllergyBiology (General)Yellow fever virusResearch Article

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

A yellow fever virus NS4B inhibitor not only suppresses viral replication, but also enhances the virus activation of RIG-I-like receptor-mediated innate immune response

FAIR Checklist

Authors (12)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)